AR068409A1 - Composiciones farmaceuticas, transdermicas sin alcohol - Google Patents
Composiciones farmaceuticas, transdermicas sin alcoholInfo
- Publication number
- AR068409A1 AR068409A1 ARP080103942A ARP080103942A AR068409A1 AR 068409 A1 AR068409 A1 AR 068409A1 AR P080103942 A ARP080103942 A AR P080103942A AR P080103942 A ARP080103942 A AR P080103942A AR 068409 A1 AR068409 A1 AR 068409A1
- Authority
- AR
- Argentina
- Prior art keywords
- agents
- composition
- dermal
- active agent
- group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 8
- 239000003795 chemical substances by application Substances 0.000 abstract 7
- MTHSVFCYNBDYFN-UHFFFAOYSA-N anhydrous diethylene glycol Natural products OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract 4
- -1 diethylene glycol ethers Chemical class 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 230000002500 effect on skin Effects 0.000 abstract 4
- 239000003961 penetration enhancing agent Substances 0.000 abstract 4
- 239000003623 enhancer Substances 0.000 abstract 3
- 239000007788 liquid Substances 0.000 abstract 3
- 230000035515 penetration Effects 0.000 abstract 3
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical class CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 239000001961 anticonvulsive agent Substances 0.000 abstract 2
- 231100000223 dermal penetration Toxicity 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 238000002663 nebulization Methods 0.000 abstract 2
- 239000000583 progesterone congener Substances 0.000 abstract 2
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 abstract 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 abstract 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Chemical class CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Chemical class CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Chemical class CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 239000005642 Oleic acid Chemical class 0.000 abstract 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Chemical class CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001800 adrenalinergic effect Effects 0.000 abstract 1
- 239000000464 adrenergic agent Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000001476 alcoholic effect Effects 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- 229940030486 androgens Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 230000003556 anti-epileptic effect Effects 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000000051 antiandrogen Substances 0.000 abstract 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 abstract 1
- 239000003173 antianemic agent Substances 0.000 abstract 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 abstract 1
- 229940125681 anticonvulsant agent Drugs 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 229940125715 antihistaminic agent Drugs 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 229940030600 antihypertensive agent Drugs 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 229940124630 bronchodilator Drugs 0.000 abstract 1
- 239000000168 bronchodilator agent Substances 0.000 abstract 1
- 239000002327 cardiovascular agent Substances 0.000 abstract 1
- 229940125692 cardiovascular agent Drugs 0.000 abstract 1
- 239000003576 central nervous system agent Substances 0.000 abstract 1
- 229940125693 central nervous system agent Drugs 0.000 abstract 1
- 239000000812 cholinergic antagonist Substances 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 229940030606 diuretics Drugs 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000003995 emulsifying agent Substances 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 229940125696 genitourinary agent Drugs 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Chemical class CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 239000003595 mist Substances 0.000 abstract 1
- 229940035363 muscle relaxants Drugs 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 229940125723 sedative agent Drugs 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 230000000475 sunscreen effect Effects 0.000 abstract 1
- 239000000516 sunscreening agent Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 229940037128 systemic glucocorticoids Drugs 0.000 abstract 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 abstract 1
- 150000003953 γ-lactams Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
Abstract
Composicion de administracion transdérmica de fármacos sin alcohol administrada mediante un dispositivo de dosificacion de fármacos de nebulizacion medida. La composicion de dosificacion transdérmica de fármacos se administra a una superficie dérmica o mucosa de un animal que necesita la misma usando un dispositivo de nebulizacion medida capaz de dosificar una nebulizacion fina de un tamano de partículas sustancialmente uniforme para minimizar el tiempo de secado requerido de la misma. Reivindicacion 1: Una composicion sin alcohol que comprende: una cantidad eficaz de uno o más agentes fisiologicamente activos; una cantidad eficaz de uno o más potenciadores de la penetracion transdérmica seleccionados entre el grupo que consiste en éteres de dietilenglicol y filtros solares de éster; y uno o más líquidos no volátiles en una composicion sin alcohol. Reivindicacion 3: La composicion de la reivindicacion 1 en la que dichos agentes activos se seleccionan entre el grupo que consiste en androgenos, anti-androgenos, estrogenos, anti-estrogenos, progestogenos, anti-progestogenos, agonistas, adrenérgicos, analgésicos, sedantes, amidas, arilpiperazinas, agentes nerviosos, antineoplásicos, agentes antiinflamatorios, anticolinérgicos, anticonvulsionantes, antidepresivos, antiepilépticos, antihistamínicos, antihipertensivos, relajantes musculares, diuréticos, broncodilatadores y glucocorticoides. Reivindicacion 4: La composicion de la reivindicacion 1 en al que dichos agentes activos se seleccionan entre el grupo que consiste en agentes alimentarios, agentes cardiovasculares, agentes sanguíneos y hemopoyéticos, agentes del sistema nervioso central, agentes musculoesqueléticos, hormonas, esteroides, agentes genitourinarios, antimicrobianos, agentes del metabolismo, agentes para alergias y del sistema inmune y agentes respiratorios. Reivindicacion 6: La composicion de la reivindicacion 1 en la que dichos potenciadores de la penetracion transdérmica se seleccionan entre el grupo que consiste en potenciadores de la penetracion de filtros solares de éter, monoalquil C1-6 éteres de dietilenglicol, derivados de laurocapram, derivados de laurocapram, ácido oleico y sus derivados de éster, ésteres de sorbitán, ésteres de ácidos grasos, ésteres de 2-pirrolidona y 2-n-nonil-1-3-dioxolano. Reivindicacion 56: Una composicion de dosificacion transdérmica de fármacos no oclusiva que comprende: (i) una cantidad terapéuticamente eficaz de al menos un agente fisiologicamente activo; (ii) al menos un potenciador de la penetracion dérmica, que está presente en una cantidad del 10 al 10.000% en peso basándose en el peso total del agente activo; (iii) al menos un líquido no volátil presente en una cantidad para actuar como vehículo para el agente activo y el potenciador de la penetracion;.donde: el potenciador de la penetracion dérmica (A) se adapta para transportar al agente fisiologicamente activo a través de una superficie dérmica o mucosa de un animal, cuando el líquido no volátil se evapora, para formar un reservorio o deposito de una mezcla que comprende el potenciador de la penetracion y el agente fisiologicamente activo dentro de dicha superficie o membrana, y (B) se tolera por la superficie dérmica o mucosa del animal; y después de la administracion de la composicion a un área de la superficie dérmica o mucosa, el área se vuelve seca a los 4 minutos de la aplicacion. Reivindicacion 65: Una composicion de acuerdo con la reivindicacion 56, que comprende adicionalmente un agente de composicion farmacéutica, codisolvente, tensioactivo, emulsionante, antioxidante, conservante, estabilizante, diluyente o una mezcla de dos o más de dichos componentes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99387407P | 2007-09-14 | 2007-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068409A1 true AR068409A1 (es) | 2009-11-18 |
Family
ID=40452524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103942A AR068409A1 (es) | 2007-09-14 | 2008-09-11 | Composiciones farmaceuticas, transdermicas sin alcohol |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090098069A1 (es) |
| AR (1) | AR068409A1 (es) |
| CA (1) | CA2699630A1 (es) |
| CL (1) | CL2008002720A1 (es) |
| PE (1) | PE20091011A1 (es) |
| WO (1) | WO2009036311A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1608378A1 (en) | 2003-04-02 | 2005-12-28 | Nexmed (Holdings), Inc. | Prostaglandin compositions and their use for the treatment of vasospasm |
| JP5833007B2 (ja) | 2009-08-31 | 2015-12-16 | ドクター・レディーズ・ラボラトリーズ・リミテッド | ステロイドを含む局所製剤 |
| CN102091326B (zh) * | 2009-12-15 | 2013-04-03 | 上海凯茂生物医药有限公司 | 治疗因肛门皮下的静脉丛发生扩大或曲张所引发的痔类疾病的经皮给药制剂及制备方法 |
| BR112013025744A2 (pt) * | 2011-04-07 | 2016-08-16 | Nexmed Holdings Inc | composicões para tratamento da doença de raynaud |
| ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| WO2014031958A1 (en) | 2012-08-24 | 2014-02-27 | Integurx Therapeutics, Llc | Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20160184431A1 (en) | 2014-03-11 | 2016-06-30 | Promius Pharma Llc | Topical compositions comprising a corticosteroid |
| US9561233B2 (en) | 2014-03-13 | 2017-02-07 | Demerx, Inc. | Use of ibogaine for the treatment of pain |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| US11696883B2 (en) | 2014-05-23 | 2023-07-11 | Triple Hair Inc. | Compositions for reducing hair loss and/or increasing hair regrowth |
| WO2015176161A1 (en) | 2014-05-23 | 2015-11-26 | Triple Hair Inc. | Compositions for reducing hair loss and/or increasing hair regrowth |
| CA2951284A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
| US9592239B2 (en) | 2014-09-12 | 2017-03-14 | Demerx, Inc. | Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake |
| PT3347009T (pt) | 2015-07-08 | 2022-01-12 | Triple Hair Inc | Composição compreendendo resveratrol e melatonina para reduzir a perda de cabelo e/ou aumentar o crescimento do cabelo |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US20170071874A1 (en) * | 2015-09-10 | 2017-03-16 | Tania Aranki | Topical analgesic |
| GB201604484D0 (en) | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
| CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| KR20240155974A (ko) | 2017-09-11 | 2024-10-29 | 아토사 테라퓨틱스, 인크. | 엔독시펜을 제조 및 사용하는 방법 |
| AU2020300624A1 (en) | 2019-07-03 | 2022-02-03 | Atossa Therapeutics, Inc. | Sustained release compositions of endoxifen |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
| US3598122A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3731683A (en) * | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
| US5304368A (en) * | 1993-02-19 | 1994-04-19 | American Telecast Corporation | Non-foaming, non-viscous, alcohol-free, water-based, pressurized hair spray product |
| US5624060A (en) * | 1995-05-02 | 1997-04-29 | Ellion; M. Edmund | Invertible dispensing system and dip tube |
| US6929801B2 (en) * | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
| US6916486B2 (en) * | 1996-02-19 | 2005-07-12 | Acrux Dds Pty Ltd | Transdermal delivery of analgesics |
| AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| US6998138B2 (en) * | 1996-02-19 | 2006-02-14 | Acrux Dds Pty. Ltd. | Topical delivery of anti-alopecia agents |
| US7094422B2 (en) * | 1996-02-19 | 2006-08-22 | Acrux Dds Pty Ltd. | Topical delivery of antifungal agents |
| US6916487B2 (en) * | 1996-02-19 | 2005-07-12 | Acrux Dds Pty Ltd | Transdermal delivery of antiemetics |
| US6923983B2 (en) * | 1996-02-19 | 2005-08-02 | Acrux Dds Pty Ltd | Transdermal delivery of hormones |
| FR2758479B1 (fr) * | 1997-01-20 | 1999-03-26 | Valois | Dispositif pour distribuer un produit fluide ou pulverulent a une distance predeterminee |
| US20040044080A1 (en) * | 1997-10-28 | 2004-03-04 | Place Virgil A. | Treatment of dyspareunia with topically administered nitroglycerin formulations |
| US6113008A (en) * | 1998-08-20 | 2000-09-05 | 3M Innovative Properties Company | Actuator system for spraying a formulation onto a host |
| WO2005039531A1 (en) * | 2003-10-10 | 2005-05-06 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| EP1325752A3 (en) * | 2000-08-03 | 2003-08-06 | Antares Pharma IPL AG | Composition for transdermal and/or transmucosal administration of active compounds which ensures adequate therapeutic levels |
| AUPR184500A0 (en) * | 2000-12-01 | 2001-01-04 | Drug Delivery Solutions Pty Ltd | Dispensing device |
| US20050181032A1 (en) * | 2002-06-25 | 2005-08-18 | Acrux Dds Pty Ltd. | Metastable pharmaceutical compositions |
| US20050186141A1 (en) * | 2002-06-25 | 2005-08-25 | Acrux Dds Pty Ltd. | Transdermal aerosol compositions |
| KR20100055542A (ko) * | 2002-06-25 | 2010-05-26 | 애크럭스 디디에스 피티와이 리미티드 | 비정질 약학적 조성물을 이용한 경피전달속도의 제어 |
| US7700076B2 (en) * | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| FR2856301B1 (fr) * | 2003-06-23 | 2007-08-03 | Galderma Res & Dev | Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile |
| JP2007512052A (ja) * | 2003-11-28 | 2007-05-17 | アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド | 迅速な経皮投与系および方法 |
| CA2548596A1 (en) * | 2003-12-10 | 2005-06-23 | Acrux Dds Pty Ltd. | Method of treatment for undesired effect following transdermal or topical drug delivery |
| PL2214643T3 (pl) * | 2007-11-02 | 2014-09-30 | Acrux Dds Pty Ltd | Układ transdermalnego dostarczania hormonów i steroidów |
-
2008
- 2008-09-11 AR ARP080103942A patent/AR068409A1/es unknown
- 2008-09-12 CL CL2008002720A patent/CL2008002720A1/es unknown
- 2008-09-12 WO PCT/US2008/076223 patent/WO2009036311A1/en not_active Ceased
- 2008-09-12 US US12/209,864 patent/US20090098069A1/en not_active Abandoned
- 2008-09-12 PE PE2008001595A patent/PE20091011A1/es not_active Application Discontinuation
- 2008-09-12 CA CA2699630A patent/CA2699630A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090098069A1 (en) | 2009-04-16 |
| WO2009036311A1 (en) | 2009-03-19 |
| CL2008002720A1 (es) | 2008-12-19 |
| PE20091011A1 (es) | 2009-08-13 |
| CA2699630A1 (en) | 2009-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068409A1 (es) | Composiciones farmaceuticas, transdermicas sin alcohol | |
| CN101883556B (zh) | 激素和类固醇的透皮递送系统 | |
| CN101932305A (zh) | 含有甾体类激素的经皮药物组合物 | |
| JP2011502173A5 (es) | ||
| US20060008432A1 (en) | Gilsonite derived pharmaceutical delivery compositions and methods: nail applications | |
| JP6487949B2 (ja) | 局所用コルチコステロイド組成物 | |
| Schroeder et al. | Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs | |
| ITMI961152A1 (it) | Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele | |
| WO2005000241A2 (en) | Compositons and methods for topical administration | |
| Caliskan et al. | Essential oils as skin permeation boosters and their predicted effect mechanisms | |
| NZ569197A (en) | Therapeutic compositions comprising ingenol angelate | |
| Singh et al. | Enhanced transdermal delivery of ketoprofen from bioadhesive gels. | |
| WO2004006960A1 (ja) | 経皮吸収製剤 | |
| US20090075963A1 (en) | Transdermal hormone spray | |
| EP1185246A1 (de) | Pharmazeutische zusammmensetzung zur nasalen anwendung von wasserunlöslichen und/oder schwer wasserlöslischen wirkstoffen | |
| JP3418423B2 (ja) | 経粘膜投与用薬剤組成物 | |
| US11246830B2 (en) | Emulsified gel composition | |
| JP2014028767A (ja) | 貼付剤 | |
| Castellano et al. | Chemical Enhancers | |
| WO2019010230A1 (en) | COMPOSITIONS FOR DRUG DELIVERY | |
| US9649384B2 (en) | Natural solubilizer agent comprising a synergistic blend of heptyl glucoside and olive oil glycereth-8 esters for transdermal compositions | |
| CN120981220A (zh) | 用于治疗脱发的包含米诺地尔的组合物 | |
| BE1021016B1 (nl) | Samenstelling voor de behandeling van nagelziektes en gebruik | |
| CN119679954A (zh) | 一种氨基酸酯生物可降解促渗剂体系的构建及应用 | |
| JPH06184000A (ja) | （−）−イソプレゴールからなる経皮吸収促進剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |